I
schemic heart disease is a major risk for mortality in diabetic patients. Coronary blood flow and coronary vascular resistance are tightly controlled by vascular tone and vascular density. Endothelial cells (ECs) serve as a major player in the regulation of vascular tone and the formation of new vessels. Thus, endothelial dysfunction is considered to be a risk factor for cardiovascular complications in many diseases. [1] [2] [3] [4] In diabetic patients, coronary endothelial dysfunction and vascular rarefaction in the heart cause cardiac ischemia and heart failure due to a shortage of vascular supply versus heart demand. [5] [6] [7] [8] [9] [10] We have recently demonstrated that capillary density in the left ventricle is significantly decreased in the heart of diabetic mice and that endothelium-dependent relaxation is significantly attenuated in diabetic coronary arteries (CAs) compared with control CAs. ] cyt is controlled by Ca 2+ mobilization from intracellular stores coupled to Ca 2+ influx from external medium. In ECs, the endoplasmic reticulum (ER) accounts for approximately 75% of the total intracellular Ca 2+ stores and the [Ca long-term signaling. Stromal interaction molecule (STIM) and Orai were identified recently as essential proteins for SOCE. 14, 15 Recent reports demonstrate that STIM1 serves as a functional sensor for SOCE and therefore contributes to Ca 2+ refilling into the ER after store depletion. [16] [17] [18] However, the role of STIM1 in coronary endothelial dysfunction in diabetes is unexplored.
In this study, we demonstrate that the increase in [Ca 2+ ] cyt due to Ca 2+ leak from the ER induced by a SERCA blocker (an indirect way to measure the Ca 2+ concentration in the ER) is significantly inhibited in mouse coronary ECs (MCECs) isolated from diabetic mice compared with ECs from control mice. Protein expression of STIM1 and SERCA3 is significantly lower in MCECs from diabetic mice than in MCECs from control mice. Not only does STIM1 overexpression in diabetic MCECs increase the amount of Ca 2+ leakage from the ER and raise [Ca 2+ ] ER toward the control level, but it also restores endothelium-dependent relaxation that was attenuated in diabetic CAs. These data suggest that the restoration of an increase in [Ca 2+ ] cyt due to Ca 2+ leak from the ER by STIM1 overexpression has a beneficial effect on coronary endothelial function, which may subsequently decrease the incidence of cardiac ischemia in diabetes.
Methods
An expanded Methods section is available in the Online Data Supplement.
Animal Preparation
All investigations conformed to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH Publication No. 85-23, Revised 1985) . This study was conducted in accordance with the guidelines established by the Institutional Animal Care and Use Committee in the University of Illinois at Chicago. Six-week-old male C57BL6 mice were purchased from Harlan Laboratories (Madison, WI); mice in the diabetic group received a single injection of streptozotocin (133 mg/kg, dissolved in citrate buffer, IV). All data were obtained from mice 6 weeks after injection. Plasma glucose levels were 10.1±0.6 mmol/L in control mice and 32.2±0.6 mmol/L in diabetic mice.
Statistical Analysis
Values are expressed as mean±SEM. Bonferroni tests for multiple statistical comparisons and Student t test for unpaired samples were carried out to identify significant differences. Differences were considered to be statistically significant when P<0.05. Figure 3A) . HG-treatment in ECs ex vivo not only downregulated STIM1 and SERCA3 protein expression ( Figure 3B ), but also inhibited the coupling of STIM1-SERCA3 in comparison to ECs treated with NG ( Figure 3C 29 and pulmonary 30 hypertension. Thus, we designed an adenovirus that encoded STIM1 positive mutant with a Tie2 promoter, which can be selectively expressed in ECs. 31, 32 As shown in Figure 4 Figure 5 ). These data suggest that STIM1 regulates Ca 2+ refilling into the ER in diabetic ECs.
Results

Hyperglycemia
It must be emphasized that in these ex vivo experiments, we did not overexpress STIM1 in diabetic MCECs above the level seen in control cells. Because STIM1 is significantly downregulated in coronary endothelial cells in diabetic mice, we actually restored the expression level of STIM1 in diabetic MCECs to the level similar to the STIM1 expression level in control MCECs. Furthermore, our experiments demonstrated that overexpression of STIM1 in HEK293 cells had no inhibitory effect on Orai1 expression and function; STIM1 overexpression actually enhances the increase in [Ca 2+ ] cyt due to Ca 2+ influx through SOC/Orai1 channels and augments Ca 2+ currents through SOC/Orai1 channels (Online Figure VII) .
Overexpression of STIM1 Restores EndotheliumDependent Vascular Relaxation That Was Attenuated in Diabetic CAs
Diabetic CAs exhibit attenuated endothelium-dependent relaxation (assessed by acetylcholine [Ach]-induced relaxation) but not smooth muscle cell-dependent relaxation (assessed by SNP).
11 STIM1-Adv or control-Adv was infected in CAs dissected from control or diabetic mice, and isometric tension experiments were performed 24 hours after infection. Figure 6A demonstrates that 10 μmol/L CPA-induced relaxation was significantly attenuated in diabetic CAs infected with control-Adv compared with control CAs infected with control-Adv. However, STIM1 overexpression in diabetic CAs significantly augmented CPA-induced vascular relaxation close to the level shown in control CAs ( Figure  6A ). ACh-induced relaxation was significantly attenuated in diabetic CAs compared with control CAs ( Figure 6B ), whereas 10 −4 mol/L SNP-induced vascular relaxation was not significantly different between control and diabetic CAs (control CAs, 99.7±3.5; diabetic CAs, 103.3±8.2; P=0.70). STIM1 overexpression significantly increased ACh-induced vascular relaxation in diabetic CAs, whereas there was no difference in SNP-induced relaxation between diabetic CAs infected with control Adv and diabetic CAs infected with STIM1-Adv ( Figure 6C ). In addition, we measured and compared nitric oxide production in control and diabetic MCECs. As shown in Figure 6D and 6E, nitric oxide production at the resting condition and during CPA treatment in the absence of extracellular Ca 2+ is decreased in diabetic MCECs compared with control MCECs, which is partially but significantly restored toward the control level by STIM1 overexpression in diabetic MCECs. These data suggest that downregulated STIM1 protein expression in coronary ECs leads to a decrease in Ca 2+ release from the ER, and subsequently attenuates endothelium-dependent relaxation in diabetic CAs. ] ER in ECs (Figure 7 ).
Inhibition of STIM1 Attenuates the
Treatment of Free Fatty Acid Significantly Decreases STIM1 mRNA and Protein Levels but HG Decreases STIM1 Protein Expression Without Changing the mRNA Level in Mouse Coronary ECs
In diabetes, plasma glucose and free fatty acid (FFA) levels are both significantly increased, and these changes trigger and progress vascular complications. We tested whether FFA or HG affects STIM1 mRNA levels and found that only FFA decreases STIM1 mRNA, however both HG and FFA significantly decrease STIM1 protein expression in ex vivo ( Figure 8 ).
Discussion
The major findings of the current study are that (1) ] cyt during CPA treatment compared with coronary ECs isolated from control mice, whereas Ca 2+ influx via SOC is not significantly different between control and diabetic MCECs (Figure 1 ). HG treatment in normal ECs significantly lowers CPA-mediated Ca 2+ leak from the ER compared with NG-treated ECs (Figure 2 ). These data imply that decreased Ca 2+ release from the ER in coronary ECs by hyperglycemia is one of the causes for attenuated coronary vascular relaxation in diabetes.
STIM, a functional sensor of stored [Ca 2+ ] in the ER, and Orai, a pore-forming subunit of SOC, were identified as 
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October 12, 2012 essential proteins for SOCE. 14, 15 In ECs, STIM1 and Orai1 are both highly expressed. 16 When the ER Ca 2+ store is depleted, STIM1 undergoes a conformational change, which allows it to multimerize, translocate to the ER-plasma membrane junction (or puncta), bind with Orai1 tetramers on the plasma membrane, activate SOC, and induce SOCE. The STIM1-mediated SOCE not only contributes to a sustained rise in [Ca 2+ ] cyt but also contributes to Ca 2+ refilling into the ER by interacting with SERCA (Online Figure V) . 17, 18 Our data demonstrate that protein expressions of STIM1 and SERCA3 are significantly decreased in MCECs isolated from diabetic mice compared with control MCECs ( Figure 3A) . Ex vivo experiments using HG reveal that HG treatment not only lowers STIM1 and SERCA3 protein expression ( Figure 3B ) but also decreases the coupling of STIM1-SERCA3 ( Figure  3C ). Further experiments are required in order to define the detailed mechanisms that cause the decrease in STIM1-SERCA3 coupling. Although STIM2 is not predominant among STIM subtypes, MCECs express STIM2, and its function in diabetic MCECs also must be examined.
One would expect to see that the decreased STIM1 protein expression in diabetic MCECs should attenuate SOCE-mediated [Ca 2+ ] cyt increase. However, contrary to our expectations, our data showed that there was no significant difference in the increase of [Ca 2+ ] cyt due to SOCE between control MCECs and diabetic MCECs ( Figure 1C, lower panels) . It has been reported that STIM1 regulates Ca 2+ refilling into the ER not only via the SOC-mediated indirect pathway but also via direct interaction with SERCA in other cell types. 17, 18 The indirect refilling mechanism is mainly caused by the uptake of increased cytosolic Ca 2+ due to SOCE via SERCA on the ER membrane. The direct refilling mechanism is that the Ca 2+ ions entered cell via SOC can be "directly" sequestered by the SERCA without slowly diffusing into the cytosol due to the STIM1-SERCA interaction, and this mechanism may be more efficient than the indirect mechanism in refilling Ca 2+ into the ER. We hypothesize that the degree of decrease in STIM1 protein expression (as shown in diabetic MCECs) is sufficient to affect the level of [Ca 2+ ] ER , but insufficient to regulate SOCE-mediated global increase in [Ca 2+ ] cyt . In addition, it is possible that other STIM1-independent mechanisms for SOCE (eg, TRPC1) may be compensatorily affected in diabetic MCECs, which makes the amplitude of SOCE comparable between control and diabetic MCECs.
In addition to the store depletion-mediated STIM1 interaction with Orai1, 16 direct interaction between SERCA3 and TRPC channels (eg, human TRPC1 and TRPC6) can be stimulated by extracellular ligand and store depletion to form the STIM/SERCA3/TRPC complex. [35] [36] [37] In human platelets, SERCA3 forms the macromolecular protein complex with TRPC1/6 and IP 3 R that is activated by store depletion or thrombin to mediate SOCE. In pulmonary vascular endothelial cells, Orai1 interacts with TRPC and regulates the ion selectivity and activation kinetics of store-operated channels. 38, 39 Physical interaction among TRPC/Orai, SERCA and STIM in vascular endothelial cells would significantly enhance the efficiency for Ca 2+ refilling into the ER (eg, via a direct refilling mechanism without a global increase in [Ca 2+ ] cyt ) and maintaining the normal endothelial function. The data from our study indicate that downregulated STIM1 (and SERCA3) in diabetic MCECs leads to a decrease in [Ca 2+ ] ER and an inhibition of endothelium-dependent coronary vasodilation. It is possible that dysfunctional (or inhibited) interaction among STIM1, SERCA3, and TRPC is also involved in the attenuated Ca 2+ refilling into the ER in diabetic ECs.
The increase in [Ca 2+ ] cyt in smooth muscle cells (SMCs) causes smooth muscle contraction and SMC proliferation, which lead to the increase in vascular tension and resistance. Indeed, upregulated STIM1/2 in SMCs has been implicated in several cardiovascular diseases. 29, 30, [40] [41] [42] In contrast, recent reports have highlighted the importance of STIM1 in endothelial physiological functions. 16, 39, 43 This current study is the first report to demonstrate the pathophysiological role of STIM1 in diabetic ECs. Since STIM1 overexpression must be selective in ECs, we designed the adenovirus that carries the Tie2 promoter so that STIM1 is only expressed in We also examined the effect of STIM1 on Ca 2+ leak from the ER in control MCECs (Online Figure I) ; overexpression of STIM1-Adv in control MCECs did not increase the rise in [Ca 2+ ] cyt after CPA treatment. It might be because that (1) the endogenous level of STIM1 protein is very high in control MCECs, therefore overexpression of exogenous STIM1 is unable to further enhance its function, and (2) the amount of SERCA in control MCECs is low and insufficient to bind to extra STIM1 to enhance Ca 2+ uptake or refilling. Endothelial dysfunction is considered to be a major risk factor for cardiovascular complications in diabetes. [44] [45] [46] The main physiological roles of ECs are the regulation of vascular tone, new vessel formation, and vascular wall permeability. It has been reported that in Type1 diabetic animal models as well as in human diabetic patients, capillary density in the heart is progressively decreased, 11, [47] [48] [49] [50] endothelium-dependent relaxation is significantly attenuated in the coronary artery, 6, 9, 11, 51, 52 and endothelial cell permeability is increased. 53 Augmented tension and increased resistance in the coronary artery lead to an insufficient delivery of oxygen to the cardiac myocyte and causes cardiac ischemia, a leading cause of mortality and mobility in diabetes. Therefore, a decrease in vascular contractility in coronary arteries should have beneficial effects on coronary vascular complications in diabetes. ACh-induced relaxation was significantly decreased in CAs in diabetic mice compared with control CAs. STIM1 overexpression not only restored CPA-induced vascular relaxation but also augments ACh-induced relaxation to the level shown in control CAs through increasing nitric oxide production ( Figure 6 ). These data suggest that a decrease in Ca 2+ release from the ER due to downregulated STIM1 protein expression in ECs is one of the causes that lead to attenuated endothelium-dependent relaxation in CAs in diabetes.
In coronary arterial SMCs, the protein expression level of STIM1 is slightly (but statistically significant) upregulated in diabetic mice in comparison to control mice. However, the 40K + -mediated coronary vasoconstriction was actually decreased in coronary arteries isolated from diabetic mice (Online Figure III) . We will further examine the function of STIM1 in diabetic SMCs in the future.
We have shown the lower expression level of SERCA3 protein in diabetic MCECs than in control MCECs (Figure 3 ). These data imply that overexpression of SERCA3 may also have beneficial effects on coronary endothelial dysfunction in diabetes. In Figure 7 , we examined the effect of STIM1 knockdown on the Ca 2+ leak from the ER, SOCE, and ] ER in diabetic MCECs but also endothelium-dependent relaxation in diabetic coronary artery in Figures 4 to 6 . These data suggest that STIM1 may play a prominent role in coronary endothelial dysfunction in diabetes. Further studies are required to determine the role of SERCA3 and its interaction with STIM1 and TRPC channels in diabetes.
We are not sure why and how STIM1 protein expression level is altered in diabetic coronary endothelial cells. In diabetes, the plasma levels of glucose and FFA are both elevated. In our ex vivo experiments, we showed that exposure of EC to high glucose and FFA significantly decreases the protein expression of STIM1, whereas only FFA decreases the mRNA expression of STIM1 (Figure 8 ). These observations suggest that increased protein degradation (eg, ubiquitinylation) and microRNA-mediated posttranscriptional modulation are potential mechanisms involved in the HG-mediated decrease in STIM1 protein level.
Taken together, our data suggest that the restoration of effective and sufficient Ca 2+ release from the ER by STIM1 overexpression improves endothelium-dependent relaxation in diabetic CAs, and may be a novel strategy to develop a therapeutic approach for cardiac ischemia in diabetes.
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